The Industry Theaters take place in the Exhibit Hall, which is open from 10:30 a.m. to 4 p.m. today.
Have lunch while listening to the latest clinical updates from supporting companies related to pulmonary, critical care, or sleep medicine. Daily Industry Theaters and Mini Theaters are available today, Monday, and Tuesday in the Exhibit Hall. All include a complimentary boxed lunch provided by the ATS (while quantities last).
SUNDAY
Noon to 12:45 p.m.
ATS Industry Theater 1
AEROSPAN™ (flunisolide) Inhalation Aerosol: A New Development
Speaker: Michael Marcus, MD, Maimonides Medical Center Director, Pediatric Pulmonary Medicine and Allergy/Immunology; Vice Chair, Pediatric Ambulatory Network; and New York University School of Medicine Clinical Associate Professor of Pediatrics
Company: MEDA Pharmaceuticals
Noon to 12:45 p.m.
ATS Industry Theater 2
Closing the Gap on Thrombotic Events
This lecture will discuss treatment options for patients with deep vein thrombosis and pulmonary embolism, and how they can reduce the risk of recurrent thrombotic events. It will also present options for reducing the risk of stroke in patients with nonvalvular atrial fibrillation.
This promotional educational activity is not accredited. The program content is developed by Janssen Pharmaceuticals, Inc. Speakers present on behalf of the company are required to present information in compliance with FDA requirements for communication about its medicines.
Speaker: William J. French, MD, Professor of Medicine, David Geffen School of Medicine at UCLA; Program Director, Interventional Cardiology; Director, Cardiac Catheterization Laboratory; Director, Anticoagulation Clinic Harbor-UCLA Medical Center Torrance, California
Company: Janssen Pharmaceuticals, Inc.
Noon to 12:45 p.m.
ATS Industry Theater 3
Small Airways, Small Particles and Patient Benefits: Time to Act?
(Open to Non-U.S. Attendees only)
This lecture will illustrate to the audience the most updated evidence concerning the detection and prevalence of small airways impairment in clinical practice. Furthermore, new data related to recent trials that assess the efficacy of small particle formulations which are able to reach and treat small airways will be presented.
Speakers: Dr. Marco Contoli, MD, PhD and Professor Peter Barnes FRS, FMedSci
Company: Chiesi Farmaceutici S.p.A.
Noon to 12:20 p.m.
ATS Mini Industry Theater
Add More to Your PAH Treatment Strategy, Even in Clinically Stable Patients
(Open to U.S. Attendees only)
Join a panel of experts for a poster-themed discussion on disease progression in patients with pulmonary arterial hypertension, adding prostacyclin class therapy earlier in appropriate patients, and how one inhaled prostacyclin class therapy can help patients manage their disease. Topics include RV assessment, clinical trial study design, efficacy, dosing, and risks. Lunch provided.
Speakers: Paul R. Forfia, MD, director, pulmonary hypertension and right heart failure program, Temple University Hospital. Philadelphia; Sean M. Studer, MD, MSc, chief of medicine, pulmonary and critical care, NYU-Woodhull Medical Center. Brooklyn, NY; and Wendy Hill, MSN, NP-C, nurse practitioner/research coordinator, pulmonary arterial hypertension program, VA Greater LA Healthcare System/UCLA. Los Angeles.
Company: United Therapeutics Corporation
12:30 to 12:50 p.m.
ATS Mini Industry Theater
Understanding the Role of Radial EBUS in Accessing Peripheral Pulmonary Nodules
The focus of this session will include the following:
Understanding and assessing Peripheral Pulmonary Nodules (PPN)
Finding the path to the target
Confirming the findings with Radial EBUS
Radial EBUS—Clinical evidence
Lunch will be provided. We look forward to seeing you there.
Speaker: Dr. Alexander Chen, MD, Director of Interventional Pulmonology at Barnes-Jewish Hospital in St. Louis, MO; Assistant Professor of Medicine and Surgery at Washington University School of Medicine Clinical and research interests include advanced diagnostic bronchoscopy for central and peripheral pulmonary lesions.
Company: Olympus America Inc.
MONDAY
Noon to 12:45 p.m.
ATS Industry Theater 2
Insights in IPF: Evolving Understanding of Idiopathic Pulmonary Fibrosis
Join an esteemed faculty for a lively interactive program that will provide insights into the evolving understanding of idiopathic pulmonary fibrosis, including its clinical course and diagnosis. The importance of high-resolution computed tomography as a diagnostic tool for physicians will be presented by an expert radiologist. Within each presentation, an audience response system will provide participants the opportunity to test their knowledge of the disease and identify characteristics indicative of IPF, as observed on HRCT scans. Please join us for a live discussion of this highly complex lung disease with experts in the field.
Speakers: Talmadge King Jr., MD; Julius R. Krevans distinguished professorship in internal medicine and chair of the department of medicine, University of California San Francisco, and Jonathan Goldin, MD, PhD, FRCR, professor, David Geffen School of Medicine at UCLA; executive vice chairman, department of radiology, and chief of radiology, Santa Monica-UCLA Medical Center, Los Angeles
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Noon to 12:45 p.m.
ATS Industry Theater 3
Addressing the Treatment Needs of the Symptomatic Patient: Are We Progressing?
(Open to Non-U.S. Based Physicians only)
This Novartis-sponsored industry theater will present, via a case-study-based approach, the importance of accurately assessing the symptoms and therapeutic needs of patients with COPD in order to achieve treatment goals of both patient and physician. Topics of discussion will include patient/physician dialog, symptom assessment, practical application of current guidelines, the central role of long-acting bronchodilators in symptomatic patients, and the importance of drug delivery systems. Clinical evidence will be presented on the use of indacaterol, a once-daily long-acting ß2-agonist, and glycopyrronium, a once-daily long-acting anticholinergic, in the treatment of COPD.
Presentations and speakers:
- Assessing the Needs of the Patient: The First Step to Better Management? Professor Ken Chapman, University of Toronto
- Patient and Physician Treatment Goals and Guidelines—Match or Mismatch? Professor M. Victorina López Varela, Hospital Maciel, Montevideo, Uruguay
- Treating the Symptomatic Patient with Once-daily Bronchodilators. Professor Peter Frith, Flinders University of South Australia, Adelaide, Australia
- The Importance of Device in the Delivery of Once-daily Bronchodilators. Professor Ken Chapman, University of Toronto
Company: Novartis Pharma AG
Noon to 12:20 p.m.
ATS Mini Industry Theater
Add More to Your PAH Treatment Strategy, Even in Clinically Stable Patients
(Open to U.S. attendees only)
Join a panel of experts for a poster-themed discussion on disease progression in patients with pulmonary arterial hypertension, adding prostacyclin class therapy earlier in appropriate patients, and how one inhaled prostacyclin class therapy can help patients manage their disease. Topics include RV assessment, clinical trial study design, efficacy, dosing, and risks. Lunch provided.
Speakers: Paul R. Forfia, MD, director, pulmonary hypertension and right heart failure program, Temple University Hospital, Philadelphia; Sean M. Studer, MD, MSc, chief of medicine, pulmonary and critical care, NYU-Woodhull Medical Center. Brooklyn, NY; and Wendy Hill, MSN, NP-C, nurse practitioner/research coordinator, pulmonary arterial hypertension program, VA Greater LA Healthcare System/UCLA. Los Angeles
Company: United Therapeutics Corporation
TUESDAY
Noon to 12:20 p.m.
ATS Mini Industry Theater
Advanced Therapies for the Complicated Sleep Disordered Breathing Patient—Part 1
Speaker: Professor Michael Arzt, University Hospital Regensburg, Germany
Company: Philips Respironics
12:30 to 12:50 p.m.
ATS Mini Industry Theater
Advanced Therapies for the Complicated Sleep Disordered Breathing Patient—Part 2
Speaker: Professor Michael Arzt, University Hospital Regensburg, Germany
Company: Philips Respironics